Øystein Garred
- Consultant; MD, PhD
Publications 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
Characterizations of uveal melanoma patients with three additional primary malignancies
Acta Ophthalmol, 102 (6), 690-696
DOI 10.1111/aos.16631, PubMed 38229427
Deep learning for automated scoring of immunohistochemically stained tumour tissue sections - Validation across tumour types based on patient outcomes
Heliyon, 10 (13), e32529
DOI 10.1016/j.heliyon.2024.e32529, PubMed 39040241
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
Publications 2023
Retinocytoma Undergoing Retinoblastoma Transformation in an Adult Patient
Case Rep Ophthalmol Med, 2023, 8127245
DOI 10.1155/2023/8127245, PubMed 37529687
Publications 2022
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103
Publications 2021
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016
Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
Cancers (Basel), 13 (23)
DOI 10.3390/cancers13236118, PubMed 34885228
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864
Publications 2020
Integrated differential DNA methylation and gene expression of formalin-fixed paraffin-embedded uveal melanoma specimens identifies genes associated with early metastasis and poor prognosis
Exp Eye Res, 203, 108426
DOI 10.1016/j.exer.2020.108426, PubMed 33387485
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Publications 2019
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Publications 2018
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530
Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
J Thromb Haemost, 16 (7), 1347-1356
DOI 10.1111/jth.14151, PubMed 29766637
Publications 2017
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0
Multicellular tumor spheroids of human uveal melanoma induce genes associated with anoikis resistance, lipogenesis, and SSXs
Mol Vis, 23, 680-694
PubMed 29033534
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer (vol 3, 35, 2017)
npj Breast Cancer, 3, 35
DOI 10.1038/s41523-017-0030-x
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
NPJ Breast Cancer, 3, 19
DOI 10.1038/s41523-017-0015-9, PubMed 28649659
Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
NPJ Breast Cancer, 3, 35
DOI 10.1038/s41523-017-0030-x, PubMed 28884144
Publications 2016
Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer
Lipids Health Dis, 15, 56
DOI 10.1186/s12944-016-0225-4, PubMed 26970778
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
Cancer Metab, 4, 12
DOI 10.1186/s40170-016-0152-x, PubMed 27350877
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
Cell Rep, 16 (7), 2032-46
DOI 10.1016/j.celrep.2016.07.028, PubMed 27498871
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb Res, 145, 78-83
DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249
Publications 2015
Bilateral uveal melanomas with different gene expression detected with 7 years interval
Acta Ophthalmol, 94 (1), 99-102
DOI 10.1111/aos.12857, PubMed 26496992
Publications 2014
Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study
Diagn Pathol, 9, 230
DOI 10.1186/s13000-014-0230-8, PubMed 25522915
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022
Publications 2007
Structural requirements for furin-induced cleavage and activation of Shiga toxin
Biochem Biophys Res Commun, 357 (1), 144-9
DOI 10.1016/j.bbrc.2007.03.110, PubMed 17407762
Publications 2006
Assessing invasion criteria in fine needle aspirates from breast carcinoma diagnosed as DICS or invasive carcinoma: can we identify an invasive component in addition to DCIS?
Acta Cytol, 50 (3), 263-70
DOI 10.1159/000325952, PubMed 16780019
Publications 2005
EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization
Diagn Cytopathol, 33 (4), 228-32
DOI 10.1002/dc.20338, PubMed 16138375
Cytologic features of ductal carcinoma in situ in fine-needle aspiration of the breast mirror the histopathologic growth pattern heterogeneity and grading
Cancer, 105 (1), 21-7
DOI 10.1002/cncr.20735, PubMed 15593325
Publications 2001
Reconstitution of clathrin-independent endocytosis at the apical domain of permeabilized MDCK II cells: requirement for a Rho-family GTPase
Traffic, 2 (1), 26-36
DOI 10.1034/j.1600-0854.2001.020105.x, PubMed 11208166
Publications 2000
Apical endocytosis of ricin in MDCK cells is regulated by the cyclooxygenase pathway
J Cell Sci, 113 ( Pt 7), 1213-21
DOI 10.1242/jcs.113.7.1213, PubMed 10704372
Apical macropinocytosis in polarized MDCK cells: regulation by N-ethylmaleimide-sensitive proteins
Eur J Cell Biol, 79 (7), 447-57
DOI 10.1078/0171-9335-00071, PubMed 10961444
Publications 1999
Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles
Mol Biol Cell, 10 (4), 961-74
DOI 10.1091/mbc.10.4.961, PubMed 10198050
Publications 1997
Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells
J Biol Chem, 272 (17), 11414-9
DOI 10.1074/jbc.272.17.11414, PubMed 9111051
Entry of Shiga toxin into cells: intracellular transport of protein toxins
Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Medical Faculty, University of Oslo, [Oslo], 1 b. (flere pag.)
BIBSYS 972822852, ISBN 82-7633-099-1
[Self-inhibiting N-glycosidase activity of shigella toxin]
Mol Biol (Mosk), 31 (3), 528-35
PubMed 9297098
Self-inhibition of N-glycosidase activity of shiga toxin
Mol. Biol., 31 (3), 441-447
Intracellular transport and processing of protein toxins produced by enteric bacteria
Adv Exp Med Biol, 412, 225-32
DOI 10.1007/978-1-4899-1828-4_34, PubMed 9192018
Publications 1996
Effect of calmodulin antagonists on endocytosis and intracellular transport of ricin in polarized MDCK cells
Exp Cell Res, 227 (2), 298-308
DOI 10.1006/excr.1996.0279, PubMed 8831568
Thapsigargin-induced transport of cholera toxin to the endoplasmic reticulum
Proc Natl Acad Sci U S A, 93 (22), 12339-43
DOI 10.1073/pnas.93.22.12339, PubMed 8901582
Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells
Mol Biol Cell, 7 (9), 1391-404
DOI 10.1091/mbc.7.9.1391, PubMed 8885234
Publications 1995
Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants
Exp Cell Res, 218 (1), 39-49
DOI 10.1006/excr.1995.1128, PubMed 7737376
Furin-induced cleavage and activation of Shiga toxin
J Biol Chem, 270 (18), 10817-21
DOI 10.1074/jbc.270.18.10817, PubMed 7738018
Diphtheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF precursor): studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells
Biochem J, 310 ( Pt 1) (Pt 1), 285-9
DOI 10.1042/bj3100285, PubMed 7646457
Publications 1994
ENTRY OF SHIGA TOXIN INTO CELLS
INT CONGR SER, 1072, 139-146
Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP
J Cell Biol, 126 (1), 53-64
DOI 10.1083/jcb.126.1.53, PubMed 8027186
Publications 1993
Entry of Shiga toxin into cells
Zentralbl Bakteriol, 278 (2-3), 296-305
DOI 10.1016/s0934-8840(11)80846-7, PubMed 8347933
Endocytosis and intracellular transport of protein toxins
Biochem Soc Trans, 21 ( Pt 3) (3), 707-11
DOI 10.1042/bst0210707, PubMed 8224494
Publications 1992
Protein toxins: mode of action and cell entry
Biochem Soc Trans, 20 (4), 724-7
DOI 10.1042/bst0200724, PubMed 1487049
Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum
Nature, 358 (6386), 510-2
DOI 10.1038/358510a0, PubMed 1641040